Two small molecule agonists of glucagon-like peptide-1 receptor modulate the receptor activation response differently.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Biochemical and Biophysical Research Communications - BBRC

• Publication date

  2012-01-06

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bbrc.2011.12.004PMID 22177947
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-Acting Glucagon-Like Peptide 1 Receptor Agonists

  2011cited by this paper
• Comparative Effects of the Endogenous Agonist Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide and the Small-Molecule Ago-Allosteric Agent “Compound 2” at the GLP-1 Receptor

  2010cited by this paper
• Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets

  2010cited by this paper
• Molecular modeling of the three-dimensional structure of GLP-1R and its interactions with several agonists

  2009cited by this paper
• A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice

  2007cited by this paper
• Small-molecule agonists for the glucagon-like peptide 1 receptor

  2007cited by this paper
• Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor.

  2007cited by this paper
• The biology of incretin hormones.

  2006cited by this paper
• Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

  2005cited by this paper
• Allosteric modulation of G-protein coupled receptors.

  2004cited by this paper
• Decreased glucagon-like peptide 1 fasting levels in type 2 diabetes.

  2003cited by this paper
• Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.

  2003cited by this paper
• Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.

  2002cited by this paper
• GPCR drug discovery through the exploitation of allosteric drug binding sites.

  2002cited by this paper
• Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration.

  2000cited by this paper
• High Potency Antagonists of the Pancreatic Glucagon-like Peptide-1 Receptor*

  1997cited by this paper
• Glucagon-like peptide-1-(7-36)amide and a rise in cyclic adenosine 3',5'-monophosphate increase cytosolic free Ca2+ in rat pancreatic beta-cells by enhancing Ca2+ channel activity.

  1993cited by this paper
• Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

  1993cited by this paper

• Binding sites and design strategies for small molecule GLP-1R agonists.

  2024cites this paper
• Discovery of small molecule positive allosteric modulators of thesecretin receptor

  2021cites this paper
• A quinoxaline-based compound ameliorates bone loss in ovariectomized mice

  2021cites this paper
• Discovery of small molecule positive allosteric modulators of the secretin receptor.

  2021cites this paper
• Molecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor

  2021cites this paper
• Non‐peptide agonists and positive allosteric modulators of glucagon‐like peptide‐1 receptors: Alternative approaches for treatment of Type 2 diabetes

  2021cites this paper
• Discovery and pharmacology of the covalent GLP-1 receptor (GLP-1R) allosteric modulator BETP: A novel tool to probe GLP-1R pharmacology.

  2020cites this paper
• An Overview, Advantages and Therapeutic Potential of Nonpeptide Positive Allosteric Modulators of Glucagon‐Like Peptide‐1 Receptor

  2019cites this paper
• Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signaling.

  2017cites this paper
• Allostery and Biased Agonism at Class B G Protein-Coupled Receptors.

  2017cites this paper
• Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes

  2016influential citation
• A Hydrogen-Bonded Polar Network in the Core of the Glucagon-Like Peptide-1 Receptor Is a Fulcrum for Biased Agonism: Lessons from Class B Crystal Structures

  2016cites this paper
• Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation

  2016cites this paper
• Signalling and Regulation of the Glucagon-like Peptide-1 receptor

  2014cites this paper
• Regulation of glucose homeostasis by GLP-1.

  2014cites this paper
• TWO Regulation of Glucose Homeostasis by GLP-1

  2013cites this paper
• Allosteric Modulation of the Activity of the Glucagon-like Peptide-1 (GLP-1) Metabolite GLP-1 9–36 Amide at the GLP-1 Receptor

  2012cites this paper